BMS's Early Oncology Head On Novel IO Approaches & Disruptions

 
• By Lucie Ellis-Taitt

BMS's early oncology chief Tim Reilly says the company's sprawling immuno-oncology pipeline might look "haphazard," but there is beauty in the bedlam.

T-cells attacking cancer_1200x675
BMS's Tim Reilly highlights novel immuno-oncology mechanisms in the company's pipeline

More from Immuno-oncology

More from Anticancer